Holen Sie sich die Stockscreener-App
0.39
2.50%
-0.01
Handel nachbörslich:
.37
-0.02
-5.13%
Schlusskurs vom Vortag:
$0.40
Offen:
$0.381
24-Stunden-Volumen:
54,587
Relative Volume:
0.02
Marktkapitalisierung:
$2.21M
Einnahmen:
$502.00K
Nettoeinkommen (Verlust:
$-8.86M
KGV:
-0.0688
EPS:
-5.67
Netto-Cashflow:
$-10.71M
1W Leistung:
-7.14%
1M Leistung:
-23.32%
6M Leistung:
-29.09%
1J Leistung:
-93.66%
1-Tages-Spanne:
$0.37
$0.399
1-Wochen-Bereich:
$0.37
$0.4889
52-Wochen-Spanne:
$0.37
$6.79
Helius Medical Technologies Inc Stock (HSDT) Company Profile
Firmenname
Helius Medical Technologies Inc
Sektor
Branche
Telefon
215-944-6100
Adresse
642 NEWTOWN YARDLEY ROAD, NEWTOWN, PA
Vergleichen Sie HSDT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HSDT
Helius Medical Technologies Inc
|
0.39 | 2.21M | 502.00K | -8.86M | -10.71M | -5.67 |
|
ABT
Abbott Laboratories
|
124.44 | 215.82B | 41.95B | 13.40B | 6.35B | 7.65 |
|
SYK
Stryker Corp
|
345.80 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
BSX
Boston Scientific Corp
|
89.70 | 132.67B | 16.75B | 1.85B | 2.37B | 1.25 |
|
MDT
Medtronic Plc
|
82.88 | 106.28B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
69.36 | 40.63B | 5.72B | 4.17B | 259.90M | 6.97 |
Helius Medical Technologies Inc Stock (HSDT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-24 | Eingeleitet | Noble Capital Markets | Outperform |
Helius Medical Technologies Inc Aktie (HSDT) Neueste Nachrichten
Helius Medical Technologies Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing - Quantisnow
Virtu Financial LLC Purchases New Shares in Helius Medical Technologies, Inc. (NASDAQ:HSDT) - Defense World
Helius Medical Unveils Revelation Neuro to Pioneer AI-Powered Neurorehabilitation - MSN
Helius Medical Creates Brain-Computer Interface Subsidiary - Medical Product Outsourcing
SEC Form 424B5 filed by Helius Medical Technologies Inc. - Quantisnow
Helius Medical Technologies Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Helius Medical Technologies Inc. (HSDT) reports earnings - Quartz
Chronic Traumatic Encephalopathy Pipeline 2025: MOA, ROA, - openPR.com
Helius Medical Technologies Inc expected to post a loss of 94 cents a shareEarnings Preview - TradingView
Chronic Traumatic Encephalopathy Treatment Market Size in 7MM - openPR.com
Helius Medical Technologies Reports Positive Preliminary Results from PoNSTEP Study - MSN
Helius Medical Technologies (HSDT) Expected to Announce Quarterly Earnings on Wednesday - The AM Reporter
Helius Medical Secures First Insurance Reimbursement for PoNS Device - MSN
Helius joins BCI landscape with new subsidiary - Yahoo
Helius Medical launches AI-driven BCI subsidiary - Investing.com Australia
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface ('BCI”) Technology Private Subsidiary - The Manila Times
Helius Medical launches AI-driven BCI subsidiary By Investing.com - Investing.com UK
Helius Medical Technologies, Inc. Announces the - GlobeNewswire
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer ... - Bluefield Daily Telegraph
Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary - TradingView
Helius Medical's New AI Brain Interface Venture Aims to Transform Neurorehabilitation Without Surgery - StockTitan
Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device - The Manila Times
Helius Medical Technologies, Inc. Announces First - GlobeNewswire
Helius Medical announces first reimbursement for PoNS Device - TipRanks
Major Breakthrough: Anthem BCBS Approves $15,420 Payment for Helius Medical's PoNS Device - StockTitan
Helius Medical Technologies, Inc. (NASDAQ: HSDT) Featured in Coverage of the 37th Annual ROTH Conference - Financial Content
Helius Medical Tech Stock Price, Quotes and Forecasts | NASDAQ:HSDT - Benzinga
Helius Medical Technologies Moves Closer to Medicare Reimbursement, Expands Stroke Program - MSN
Neurology Devices Market Detailed In New Research Report 2025 | - openPR
Research Reports on BELLUS Health Helius Medical Technologies, Resverlogix, and Crescita Therapeutics - ACCESS Newswire
Helius Medical faces Nasdaq delisting over bid price By Investing.com - Investing.com Canada
Helius Medical Technologies (NASDAQ:HSDT) Shares Down 5.8% – What’s Next? - Armenian Reporter
Helius Medical faces Nasdaq delisting over bid price - Investing.com
Helius Medical Technologies IncContinues Non-Compliance With Nasdaq Minimum Bid Price Requirement - Marketscreener.com
Helius Medical Technologies (NASDAQ:HSDT) Trading Down 5.8% – Should You Sell? - Defense World
Enrollment for Helius Stroke Pivotal Study Exceeds Initial Target - Physical Therapy Products
PoNS therapy shows promise for MS gait deficits - MSN
PoNSTEP Study Confirms Long-Term Benefits of PoNS Therapy for MS Patients - MSN
Helius Medical Secures Funds Through Warrant Agreements - TipRanks
HSDTHelius Medical Technologies, Inc. Latest Stock News & Market Updates - StockTitan
Helius Medical Surpasses Enrollment Target for Stroke Program - MSN
Helius Medical Technologies, Inc. Announces Exercise of - GlobeNewswire
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study - The Manila Times
Helius Medical Technologies, Inc. Announces First Clinical - GlobeNewswire
Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term ... - The Bakersfield Californian
Helius exceeds stroke study enrollment goals By Investing.com - Investing.com Australia
Finanzdaten der Helius Medical Technologies Inc-Aktie (HSDT)
Umsatz
Nettogewinn
Free Cashflow
ENV
7.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):